{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:16:59Z","timestamp":1760235419077,"version":"build-2065373602"},"reference-count":33,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Treatment for elderly (aged \u226575 years) patients with rheumatoid arthritis (RA) is important because they usually have several complications and organ dysfunction and are more susceptible to drug-related adverse events. Abatacept (ABT) treatment is relatively safe in elderly RA patients; however, the real-world data of efficacy and long-term retention of ABT is sparse in such patients. This study aimed to investigate the clinical efficacy and long-term retention rates of ABT in elderly Japanese RA patients. Materials and Methods: This 10-year retrospective observational cohort study was performed in two centers in Fukushima, Japan. We reviewed the clinical features of elderly RA patients who received ABT and investigated the differences in retention rates with concomitant administration of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Results: The clinical characteristics of younger (&lt;75 years old, 39 cases) and elderly (\u226575 years old, 20 cases) RA patients were generally similar. Although the efficacy was also similar, the concomitant administration of csDMARDs with ABT differed between the two groups. Younger patients significantly decreased methotrexate (MTX) administration than elderly patients (p &lt; 0.01), and elderly patients significantly received tacrolimus (TAC) (p &lt; 0.01) or salazosulfapyridine (SASP; p = 0.01) than younger patients. The overall retention and infection-free survival rates were similar between the two groups. Conclusion: Elderly RA patients showed sustained retention rates compared to younger RA patients. TAC and SASP can help to maintain sustained retention rates in elderly RA patients.<\/jats:p>","DOI":"10.3390\/medicina57090914","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T08:42:32Z","timestamp":1630399352000},"page":"914","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis"],"prefix":"10.3390","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8110-8261","authenticated-orcid":false,"given":"Shuzo","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jumpei","family":"Temmoku","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Yashiro-Furuya","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ohta Nishinouchi Hospital, Koriyama 963-8558, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kanno","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ohta Nishinouchi Hospital, Koriyama 963-8558, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Migita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/1756-185X.12998","article-title":"The age at onset of rheumatoid arthritis is increasing in Japan: A nationwide database study","volume":"20","author":"Kato","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0021-9681(63)90016-X","article-title":"Human aging and disease","volume":"16","author":"Kohn","year":"1963","journal-title":"J. Chronic. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/rheumatology\/kev437","article-title":"Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology\u2019s ORA registry","volume":"55","author":"Lahaye","year":"2016","journal-title":"Rheumatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/14397595.2018.1524998","article-title":"Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance","volume":"29","author":"Harigai","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3109\/14397595.2015.1123211","article-title":"Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis","volume":"26","author":"Harigai","year":"2016","journal-title":"Mod. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13075-019-1921-z","article-title":"Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: Data from an observational study","volume":"21","author":"Ozen","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ebina, K., Hashimoto, M., Yamamoto, W., Ohnishi, A., Kabata, D., Hirano, T., Hara, R., Katayama, M., Yoshida, S., and Nagai, K. (2018). Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis\u2013The ANSWER cohort study. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0194130"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13075-020-02233-9","article-title":"Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry","volume":"22","author":"Kawabe","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00296-020-04619-z","article-title":"Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: A sub-analysis of the international, observational ACTION study","volume":"40","author":"Westhovens","year":"2020","journal-title":"Rheumatol. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3109\/s10165-012-0760-4","article-title":"Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients","volume":"23","author":"Takahashi","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1097\/MJT.0000000000000645","article-title":"Abatacept Monotherapy Versus Abatacept Plus Methotrexate for Treatment-Refractory Rheumatoid Arthritis","volume":"26","author":"Pascart","year":"2019","journal-title":"Am. J. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Mori, S., Hidaka, M., Kawakita, T., Hidaka, T., Tsuda, H., Yoshitama, T., Migita, K., and Ueki, Y. (2016). Factors Associated with Myelosuppression Related to Low-Dose Methotrexate Therapy for Inflammatory Rheumatic Diseases. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0154744"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00296-020-04547-y","article-title":"Methotrexate-related toxicity in patients with rheumatoid arthritis and renal dysfunction","volume":"40","author":"Lee","year":"2020","journal-title":"Rheumatol. Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fmed.2019.00238","article-title":"Methotrexate-Associated Pneumonitis and Rheumatoid Arthritis-Interstitial Lung Disease: Current Concepts for the Diagnosis and Treatment","volume":"6","author":"Fragoulis","year":"2019","journal-title":"Front. Med. (Lausanne)"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2000337","DOI":"10.1183\/13993003.00337-2020","article-title":"Methotrexate and rheumatoid arthritis associated interstitial lung disease","volume":"57","author":"Juge","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e005615","DOI":"10.1136\/bmjopen-2014-005615","article-title":"Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis","volume":"4","author":"Nakashita","year":"2014","journal-title":"BMJ Open"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semarthrit.2017.12.012","article-title":"Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients","volume":"48","author":"Loricera","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_18","unstructured":"Bristol-Myers Squibb (2021, May 28). Orencia (Abatacept) Prescribing Information. Available online: http:\/\/packageinserts.bms.com\/pi\/pi_orencia.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/acr2.1034","article-title":"Safety of Abatacept Versus Placebo in Rheumatoid Arthritis: Integrated Data Analysis of Nine Clinical Trials","volume":"1","author":"Simon","year":"2019","journal-title":"ACR Open Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e000813","DOI":"10.1136\/rmdopen-2018-000813","article-title":"Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: A randomised placebo-controlled phase IV study","volume":"4","author":"Matsubara","year":"2018","journal-title":"RMD Open"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5387\/fms.57.54","article-title":"Effect of additional administration of tacrolimus in patients with rheumatoid arthritis treated with biologics","volume":"57","author":"Miyata","year":"2011","journal-title":"Fukushima J. Med. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40268-015-0106-8","article-title":"Evaluation of the Safety and Effectiveness of Add-On Tacrolimus in Patients with Rheumatoid Arthritis Who Failed to Show an Adequate Response to Biological DMARDs: The Interim Results of a Specific Drug Use-Results Survey of Tacrolimus","volume":"15","author":"Ishida","year":"2015","journal-title":"Drugs R D"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/1759720X16665330","article-title":"Combination therapy with biologic agents in rheumatic diseases: Current and future prospects","volume":"8","author":"Inui","year":"2016","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/rheumatology\/kei172","article-title":"Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients","volume":"45","author":"Kawai","year":"2006","journal-title":"Rheumatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/03009740903501642","article-title":"Tacrolimus for the treatment of active rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials","volume":"39","author":"Lee","year":"2010","journal-title":"Scand. J. Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3904\/kjim.2015.385","article-title":"Drug survival and the associated predictors in South Korean patients with rheumatoid arthritis receiving tacrolimus","volume":"33","author":"Park","year":"2018","journal-title":"Korean J. Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/14397595.2017.1332471","article-title":"Safety and effectiveness of tacrolimus add-on therapy for rheumatoid arthritis patients without an adequate response to biological disease-modifying anti-rheumatic drugs (DMARDs): Post-marketing surveillance in Japan","volume":"28","author":"Takeuchi","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3109\/14397595.2015.1029238","article-title":"Comparison of efficacy and safety of tacrolimus and methotrexate in combination with abatacept in patients with rheumatoid arthritis; a retrospective observational study in the TBC Registry","volume":"25","author":"Fujibayashi","year":"2015","journal-title":"Mod. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1111\/1756-185X.13731","article-title":"Clinical effectiveness and safety of additional administration of tacrolimus in rheumatoid arthritis patients with an inadequate response to abatacept: A retrospective cohort study","volume":"22","author":"Suzuki","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00011-004-1284-y","article-title":"Inflammatory cytokine levels in paw tissues during development of rat collagen-induced arthritis: Effect of FK506, an inhibitor of T cell activation","volume":"53","author":"Magari","year":"2004","journal-title":"Inflamm. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/sj.bjp.0703472","article-title":"FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells","volume":"130","author":"Sakuma","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1093\/rheumatology\/kez604","article-title":"Abatacept in rheumatoid arthritis and the risk of cancer: A world observational post-marketing study","volume":"59","author":"Bagheri","year":"2020","journal-title":"Rheumatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13075-019-1992-x","article-title":"Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: A multi-database real-world study","volume":"21","author":"Simon","year":"2019","journal-title":"Arthritis Res. Ther."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/9\/914\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:53:13Z","timestamp":1760165593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/9\/914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["medicina57090914"],"URL":"https:\/\/doi.org\/10.3390\/medicina57090914","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2021,8,31]]}}}